In­cyte antes up $200M — promis­es bil­lions more — to launch a bis­pe­cif­ic de­vel­op­ment deal with Merus

In­cyte is em­brac­ing Dutch biotech Merus and its bis­pe­cif­ic an­ti­body tech, agree­ing to buy in­to a new dis­cov­ery and de­vel­op­ment col­lab­o­ra­tion that starts with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER